HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The endocannabinoid system as a target for the treatment of motor dysfunction.

Abstract
There is evidence that cannabinoid-based medicines that are selective for different targets in the cannabinoid signalling system (e.g. receptors, inactivation mechanism, enzymes) might be beneficial in basal ganglia disorders, namely Parkinson's disease (PD) and Huntington's disease (HD). These benefits not only include the alleviation of specific motor symptoms [e.g. choreic movements with cannabinoid receptor type 1 (CB(1))/transient receptor potential vanilloid type 1 agonists in HD; bradykinesia with CB(1) antagonists and tremor with CB(1) agonists in PD], but also the delay of disease progression due to the neuroprotective properties demonstrated for cannabinoids (e.g. CB(1) agonists reduce excitotoxicity; CB(2) agonists limit the toxicity of reactive microglia; and antioxidant cannabinoids attenuate oxidative damage). In addition, extensive biochemical, anatomical, physiological and pharmacological studies have demonstrated that: (i) the different elements of the cannabinoid system are abundant in basal ganglia structures and they are affected by these disorders; (ii) the cannabinoid system plays a prominent role in basal ganglia function by modulating the neurotransmitters that operate in the basal ganglia circuits, both in healthy and pathological conditions; and (iii) the activation and/or inhibition of the cannabinoid system is associated with important motor responses that are maintained and even enhanced in conditions of malfunctioning and/or degeneration. In this article we will review the available data regarding the relationship between the cannabinoid system and basal ganglia activity, both in healthy and pathological conditions and will also try to identify future lines of research expected to increase current knowledge about the potential therapeutic benefits of targeting this system in PD, HD and other basal ganglia disorders.
AuthorsJavier Fernández-Ruiz
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 156 Issue 7 Pg. 1029-40 (Apr 2009) ISSN: 1476-5381 [Electronic] England
PMID19220290 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Cannabinoid Receptor Modulators
  • Cannabinoids
  • Endocannabinoids
  • Receptor, Cannabinoid, CB1
  • Receptor, Cannabinoid, CB2
  • TRPV Cation Channels
  • TRPV1 protein, human
Topics
  • Basal Ganglia (metabolism)
  • Basal Ganglia Diseases (drug therapy, metabolism, physiopathology)
  • Cannabinoid Receptor Modulators (physiology)
  • Cannabinoids (therapeutic use)
  • Endocannabinoids
  • Humans
  • Huntington Disease (drug therapy, metabolism, physiopathology)
  • Movement Disorders (drug therapy, metabolism, physiopathology)
  • Parkinson Disease (drug therapy, metabolism, physiopathology)
  • Receptor, Cannabinoid, CB1 (agonists, antagonists & inhibitors)
  • Receptor, Cannabinoid, CB2 (agonists)
  • Signal Transduction
  • TRPV Cation Channels (agonists)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: